Nucs AI is a medical imaging AI company focused on oncology diagnostics. The company develops a platform that automates the detection, staging, and treatment response evaluation of prostate cancer through analysis of PSMA-PET/CT scans. Its suite includes DeepPSMA, SelectPSMA, and TrackPSMA.
The platform's reported metrics include 92% accuracy in identifying PSMA-positive lesions, scan processing times of under a minute, and elimination of manual work in over 50% of cases. The company states its mission is advancing faster, more precise diagnostic tools to improve patient outcomes by redefining how AI and imaging work together.
Nucs AI has a presence in San Francisco and Berlin. The company raised $3.5 million in a seed funding round. Its core technical domains span medical imaging AI, computer vision, machine learning, and oncology diagnostics.
